Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2005
12/29/2005DE102004022574A1 Pharmaceutical formulation, for use in inflammatory disorders, identifies the rabies virus protein P as an interferon antagonist with substitution of the P-coded nucleic acid sequence
12/29/2005CA2847677A1 Methods for treating conditions associated with masp-2 dependent complement activation
12/29/2005CA2612146A1 Treating cancer
12/29/2005CA2608862A1 Silk-based drug delivery system
12/29/2005CA2579605A1 Topical compositions and methods for epithelial-related conditions
12/29/2005CA2575101A1 Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
12/29/2005CA2573144A1 Methods for treating conditions associated with masp-2 dependent complement activation
12/29/2005CA2570330A1 Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
12/29/2005CA2570271A1 Method of enhancing the immune response to a vaccine
12/29/2005CA2570267A1 Fgfr binding peptides
12/29/2005CA2570218A1 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
12/29/2005CA2569807A1 Oligomeric peptides and their use for the treatment of hiv infections
12/29/2005CA2569687A1 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
12/29/2005CA2569368A1 Photochromic material comprising a proteorhodopsin apoprotein and retinal analog
12/29/2005CA2568902A1 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids
12/29/2005CA2568643A1 Treatment of non alcoholic steatotic hepatitis (nash)
12/29/2005CA2568601A1 Peptide-based compounds
12/29/2005CA2568543A1 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
12/29/2005CA2568384A1 Immune response suppressor and treatment of multiple sclerosis
12/29/2005CA2567686A1 Use of vegf inhibitors for the treatment of human cancer
12/29/2005CA2510823A1 Hemostatic compositions and devices
12/28/2005EP1609864A2 Use of neuronal apoptosis inhibitor protein (NAIP)
12/28/2005EP1609863A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/28/2005EP1609861A1 Low-molecular weight peptides inhibiting ion channel activity
12/28/2005EP1609860A1 Seb modification and preventive/remedy for diseases with immune abnormality contianing the same
12/28/2005EP1609856A2 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof
12/28/2005EP1609853A1 Process for controlling sialylation of proteins produced by mammalian cell culture
12/28/2005EP1609802A1 Transcriptional factor inducing apoptosis in cancer cell
12/28/2005EP1609801A1 Proteins of natural origin and materials made therefrom
12/28/2005EP1609484A1 Cancer treatment with endothelin receptor antagonists
12/28/2005EP1609482A1 Drug for treating hemophilia and method of treating hemophilia using the same
12/28/2005EP1609478A1 Exendin agonist peptide formulations
12/28/2005EP1609477A1 Irrigation solution and use thereof for the perioperative inhibition of pain/inflammation and/or spasm at a vascular structure
12/28/2005EP1609468A2 A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
12/28/2005EP1608970A2 Ccn3 compositions and methods
12/28/2005EP1608776A2 Methods for monitoring drug activities in vivo
12/28/2005EP1608754A2 Modulation of cell phenotype by inhibitory rna
12/28/2005EP1608753A1 Antisense oligonucleotides (odn) against smad7 and uses in medical field thereof
12/28/2005EP1608745A2 FVII OR FVIIa VARIANTS
12/28/2005EP1608742A1 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b)
12/28/2005EP1608736A2 Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof
12/28/2005EP1608730A2 Truncated baff receptors
12/28/2005EP1608729A2 Rnai arrays and methods for using the same
12/28/2005EP1608688A2 Branched water-soluble polymers and their conjugates
12/28/2005EP1608685A2 Methods of treating diabetes by blocking vegf-mediated activity
12/28/2005EP1608680A2 Glp-2 derivatives
12/28/2005EP1608679A1 Dystrophin-related protein (drop1), a marker for carcinomas
12/28/2005EP1608672A2 Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
12/28/2005EP1608457A1 Use of recombinant albumin in dialysis after liver failure
12/28/2005EP1608417A1 Method and system for colloid exchange therapy
12/28/2005EP1608411A2 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
12/28/2005EP1608409A2 Peptides selectively lethal to malignant and transformed mammalian cells
12/28/2005EP1608404A2 Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (gitr or tnfrsf18)
12/28/2005EP1608402A1 Improved vaccines
12/28/2005EP1608401A1 Use of alum and a th1 immune response inducing adjuvant for enhancing immune respones
12/28/2005EP1608400A1 Elevation of adenosine level by cytokine-induced expression of cd73
12/28/2005EP1608399A2 Ligands for tgf--beta binding proteins and uses thereof
12/28/2005EP1608398A2 Use of dg931 protein for treating diabetes, obesity and metabolic syndrome
12/28/2005EP1608397A1 S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
12/28/2005EP1608396A2 Use of soluble cd14 for treatment of diseases
12/28/2005EP1608395A1 Anticancer agent comprising lk8 protein as an active ingredient
12/28/2005EP1608394A2 Modulators
12/28/2005EP1608393A2 Ebola peptides and immunogenic compositions containing same
12/28/2005EP1608392A2 Papanicolau staining process
12/28/2005EP1608391A2 Composition for inducing of immunotolerance
12/28/2005EP1608390A2 Correlation of gene expression with chromosome abnormalities in ataxia telangiectasia tumorigenesis
12/28/2005EP1608384A2 Therapy for primary and metastatic cancers
12/28/2005EP1608366A1 Use of ritonavir for the treatment of unconjugated hyperbilirubinemia
12/28/2005EP1608351A2 Compositions containing superoxide dismutase and a selected et 5-lipoxygenase inhibitor and uses thereof
12/28/2005EP1608321A2 Cytokine-expressing cellular vaccine combinations
12/28/2005EP1608320A2 Novel imidazoline receptor homologs
12/28/2005EP1608319A2 Improved inhibitors for the soluble epoxide hydrolase
12/28/2005EP1608318A2 Cxcr4 antagonists and methods of their use
12/28/2005EP1608316A2 Methods and compositions for treating and preventing inflammatory conditions
12/28/2005EP1608315A2 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
12/28/2005EP1608314A2 Novel probiotic compositions and methods of using the same
12/28/2005EP1608313A2 Facially amphiphilic polymers and oligomers and uses thereof
12/28/2005EP1608311A1 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
12/28/2005EP1608308A2 Anti-inflammatory activity from lactic acid bacteria
12/28/2005EP1608307A2 An antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
12/28/2005EP1608255A2 Breast endothelial cell expression patterns
12/28/2005EP1581904A3 Novel proteins with altered immunogenicity
12/28/2005EP1490013A4 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
12/28/2005EP1434779B1 Cross-linked glycopeptide-cephalosporin antibiotics
12/28/2005EP1401502B1 Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
12/28/2005EP1401471A4 Composition and method for treating cells
12/28/2005EP1364029B1 FUSION PROTEIN comprising hirudin and proinsulin or insulin
12/28/2005EP1330258B1 Kahalalide f formulation
12/28/2005EP1274454B1 Methods and compositions for eliciting an immune response
12/28/2005EP1265867B1 Malonic acid derivates, processes for their preparation, their use as inhibitor of factor xa activity and pharmaceutical compositions containing them
12/28/2005EP1251843B1 Compositions for delivery of a cortisol antagonist
12/28/2005EP1234581B1 Use of secretory leucocyte protease inhibitor for keloid and scars
12/28/2005EP1161418B1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors
12/28/2005EP1156811B1 Copper agonist that binds on the copper binding site of amyloid precursor protein (app) and/or exerts an inhibiting effect on the release of amyloid-beta-peptide
12/28/2005EP1123114B1 Virus-like particles for the induction of autoantibodies
12/28/2005EP1085909B1 A complex of alpha-fetoprotein (AFP) and a polyunsaturated fatty acid derivative for the treatment of immune deficiencies
12/28/2005EP1082128B1 Lysine containing peptides for treatment of heart disease
12/28/2005EP1073683B1 G-csf receptor agonist antibodies and screening method therefor
12/28/2005EP1025227B1 Human toll homologues
12/28/2005EP1021544B1 Chimeric vaccine against tick-borne encephalitis virus
1 ... 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 ... 3163